Citations (61)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Mikkel Højlund & Christoph U. Correll. (2023) Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches. Expert Opinion on Pharmacotherapy 24:13, pages 1463-1489.
Read now
Read now
Leslie Citrome, Emily Belcher, Sylvie Stacy, Mark Suett, Marko Mychaskiw & Gregory D Salinas. (2022) Perceived Burdens and Educational Needs of Caregivers of People with Schizophrenia: Results of a National Survey Study. Patient Preference and Adherence 16, pages 159-168.
Read now
Read now
Renato de Filippis, Pasquale De Fazio, Raffaele Gaetano, Luca Steardo, Clemente Cedro, Antonio Bruno, Rocco Antonio Zoccali & Maria Rosaria Anna Muscatello. (2021) Current and emerging long-acting antipsychotics for the treatment of schizophrenia. Expert Opinion on Drug Safety 20:7, pages 771-790.
Read now
Read now
Maju Mathews, Srihari Gopal, Isaac Nuamah, Ludger Hargarter, Adam J Savitz, Edward Kim, Wilson Tan, Bernardo Soares & Christoph U Correll. (2019) Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia. Neuropsychiatric Disease and Treatment 15, pages 1365-1379.
Read now
Read now
Leslie Citrome. (2017) Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications. Expert Review of Neurotherapeutics 17:10, pages 1029-1043.
Read now
Read now
Leslie Citrome. (2016) Schizophrenia relapse, patient considerations, and potential role of lurasidone. Patient Preference and Adherence 10, pages 1529-1537.
Read now
Read now
Eva G Katz, Brett Hauber, Srihari Gopal, Angie Fairchild, Amy Pugh, Rachel B Weinstein & Bennett S Levitan. (2016) Physician and patient benefit–risk preferences from two randomized long-acting injectable antipsychotic trials. Patient Preference and Adherence 10, pages 2127-2139.
Read now
Read now
Ludovic Samalin, Ricardo Garay, Ahcène Ameg & Pierre-Michel Llorca. (2016) Olanzapine pamoate for the treatment of schizophrenia – a safety evaluation. Expert Opinion on Drug Safety 15:3, pages 403-411.
Read now
Read now
Leslie Citrome. (2016) Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. Expert Review of Clinical Pharmacology 9:2, pages 169-186.
Read now
Read now
Srihari Gopal, An Vermeulen, Partha Nandy, Paulien Ravenstijn, Isaac Nuamah, José Antonio Buron Vidal, Joris Berwaerts, Adam Savitz, David Hough & Mahesh N. Samtani. (2015) Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia. Current Medical Research and Opinion 31:11, pages 2043-2054.
Read now
Read now
Peter M Haddad, Cecilia Brain & Jan Scott. (2014) Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Related Outcome Measures 5, pages 43-62.
Read now
Read now
Sheng-Min Wang, Changsu Han, Soo-Jung Lee, Ashwin A Patkar, Prakash S Masand & Chi-Un Pae. (2014) Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection. Neuropsychiatric Disease and Treatment 10, pages 1605-1611.
Read now
Read now
Leslie Citrome, Siddhesh A. Kamat, Christophe Sapin, Ross A. Baker, Anna Eramo, Jesse Ortendahl, Benjamin Gutierrez, Karina Hansen & Tanya G. K. Bentley. (2014) Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. Journal of Medical Economics 17:8, pages 567-576.
Read now
Read now
Articles from other publishers (48)
Junji Wang, Junfeng Liu, Jingwen Ding, Qin Li, Yuan Zhao, Dongxu Gao, Keyi Su, Yani Yang, Zhefeng Wang & Jun He. (2023) Creation of a ready-to-use brexpiprazole suspension and the inflammation-mediated pharmacokinetics by intramuscular administration. European Journal of Pharmaceutics and Biopharmaceutics 189, pages 189-201.
Crossref
Crossref
Giuseppe Cicala, Renato de Filippis, Maria Antonietta Barbieri, Paola Maria Cutroneo, Pasquale De Fazio, Georgios Schoretsanitis & Edoardo Spina. (2023) Tolerability profile of paliperidone palmitate formulations: A pharmacovigilance analysis of the EUDRAVigilance database. Frontiers in Psychiatry 14.
Crossref
Crossref
Inmaculada Baeza, Adriana Fortea, Daniel Ilzarbe & Gisela Sugranyes. (2023) What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review. Pediatric Drugs 25:2, pages 135-149.
Crossref
Crossref
Ilaria Riboldi, Daniele Cavaleri, Chiara A Capogrosso, Cristina Crocamo, Francesco Bartoli & Giuseppe Carrà. (2022) Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia. Psychology Research and Behavior Management Volume 15, pages 3915-3929.
Crossref
Crossref
Natasa Borojevic, Midya Dawud, Junhua Xiao & Yang Yun. (2022) Long-acting injectable paliperidone palmitate induced severe cutaneous allergic reaction in a patient with first episode delusional disorder tolerating oral paliperidone regimen: a case report. BMC Psychiatry 22:1.
Crossref
Crossref
Samantha Socco, Archana Jhawar & Michael A. Riddle. (2021) The use of carbamazepine to expedite the metabolism of a long‐acting aripiprazole injection. Journal of Clinical Pharmacy and Therapeutics 47:4, pages 562-566.
Crossref
Crossref
Naoto Adachi & Masumi Ito. (2022) Epilepsy in patients with schizophrenia: Pathophysiology and basic treatments. Epilepsy & Behavior 127, pages 108520.
Crossref
Crossref
Leslie Citrome, Emily Belcher, Sylvie Stacy, Mark Suett, Marko Mychaskiw & Gregory D Salinas. (2022) Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians. Neuropsychiatric Disease and Treatment Volume 18, pages 111-123.
Crossref
Crossref
Oliver D. Howes, Michael E. Thase & Toby Pillinger. (2021) Treatment resistance in psychiatry: state of the art and new directions. Molecular Psychiatry 27:1, pages 58-72.
Crossref
Crossref
Preeti Jacob, Siddhesh Shere & John Vijay Sagar Kommu. (2021) The use of first-generation long-acting injectable antipsychotics in children and adolescents—A retrospective audit from India. Asian Journal of Psychiatry 61, pages 102663.
Crossref
Crossref
Leslie Citrome. (2021) Long-acting injectable antipsychotics: what, when, and how. CNS Spectrums 26:2, pages 118-129.
Crossref
Crossref
Dalibor Karlović, Ante Silić, Danijel Crnković & Vjekoslav Peitl. (2020) Effects of aripiprazole long‐acting injectable antipsychotic on hospitalization in recent‐onset schizophrenia. Human Psychopharmacology: Clinical and Experimental 36:2.
Crossref
Crossref
Georgios SchoretsanitisPierre BaumannAndreas ConcaOtto DietmaierGiancarlo GiupponiGerhard GründerMartina HahnXenia HartUrsula Havemann-ReineckeGudrun HefnerMaxim KuzinRainald MössnerDaria PiacentinoWerner SteimerGerald Zernig & Christoph Hiemke. (2021) Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic Drugs. Therapeutic Drug Monitoring 43:1, pages 79-102.
Crossref
Crossref
Jinghua Xu, Yanjie Bai, Xuehui Li, Zhenping Wei, Lu Sun, Hongdan Yu & Hui Xu. (2021) Porous Core/Dense Shell PLA Microspheres Embedded with High Drug Loading of Bupivacaine Crystals for Injectable Prolonged Release. AAPS PharmSciTech 22:1.
Crossref
Crossref
Leslie Citrome & Jan Volavka. (2021) Specific Anti-hostility Effects of Atypical Antipsychotics in Persons with Schizophrenia: From Clozapine to Cariprazine. Harvard Review of Psychiatry 29:1, pages 20-34.
Crossref
Crossref
Massimo Carlo Mauri, Alessandra Reggiori, Alessandro Minutillo, Gemma Franco, Chiara Di Pace, Silvia Paletta & Dario Cattaneo. (2020) Paliperidone LAI and Aripiprazole LAI Plasma Level Monitoring in the
Prophylaxis of Bipolar Disorder Type I with Manic Predominance. Pharmacopsychiatry 53:05, pages 209-219.
Crossref
Crossref
Samer Hammoudeh, Hawra Al Lawati, Suhaila Ghuloum, Huma Iram, Arij Yehya, Imen Becetti, Nora Al-fakhri, Hany Ghabrash, Mena Shehata, Nighat Ajmal, Iman Amro, Hira Safdar, Yassin Eltorki & Hassen Al-Amin. (2019) Risk Factors of Metabolic Syndrome Among Patients Receiving Antipsychotics: A Retrospective Study. Community Mental Health Journal 56:4, pages 760-770.
Crossref
Crossref
Iara Carolina Barbosa Henrique, Tácio Lima, Daniela Oliveira Melo & Patricia Melo Aguiar. (2019) Economic evaluations on the use of aripiprazole for patients with schizophrenia: A systematic review. Journal of Clinical Pharmacy and Therapeutics 45:1, pages 1-15.
Crossref
Crossref
Thomas RE Barnes, Richard Drake, Carol Paton, Stephen J Cooper, Bill Deakin, I Nicol Ferrier, Catherine J Gregory, Peter M Haddad, Oliver D Howes, Ian Jones, Eileen M Joyce, Shôn Lewis, Anne Lingford-Hughes, James H MacCabe, David Cunningham Owens, Maxine X Patel, Julia MA Sinclair, James M Stone, Peter S Talbot, Rachel Upthegrove, Angelika Wieck & Alison R Yung. (2019) Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 34:1, pages 3-78.
Crossref
Crossref
Adam J. Savitz, Haiyan Xu, Srihari Gopal, Isaac Nuamah, Maju Mathews & Bernardo Soares. (2019) Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies. Brazilian Journal of Psychiatry 41:6, pages 499-510.
Crossref
Crossref
Luisa Peters, Amanda Krogmann, Laura von Hardenberg, Katja Bödeker, Viktor B. Nöhles & Christoph U. Correll. (2019) Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016–March 2019. Current Psychiatry Reports 21:12.
Crossref
Crossref
Dhruvkumar Soni, Aditya N. Bade, Nagsen Gautam, Jonathan Herskovitz, Ibrahim M. Ibrahim, Nathan Smith, Melinda S. Wojtkiewicz, Bhagya Laxmi Dyavar Shetty, Yazen Alnouti, JoEllyn McMillan, Howard E. Gendelman & Benson J. Edagwa. (2019) Synthesis of a long acting nanoformulated emtricitabine ProTide. Biomaterials 222, pages 119441.
Crossref
Crossref
Christoph U. Correll, Jennifer Kern Sliwa, Dean M. Najarian & Stephen R. Saklad. (2018) Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable antipsychotics. CNS Spectrums 24:4, pages 354-370.
Crossref
Crossref
M. C. Mauri & C. Di Pace. 2019. Clinical Cases in Psychiatry: Integrating Translational Neuroscience Approaches. Clinical Cases in Psychiatry: Integrating Translational Neuroscience Approaches
245
257
.
Jennifer Kern Sliwa, Adam Savitz, Isaac Nuamah, Maju Mathews, Srihari Gopal, Erica Elefant, Dean Najarian & Larry Alphs. (2018) An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitate. Perspectives in Psychiatric Care 54:4, pages 530-538.
Crossref
Crossref
Adriana ForteaDaniel IlzarbeLaura EspinosaMireia SolerdelcollClara de CastroGiovanni OrioloGisela SugranyesInmaculada Baeza. (2018) Long-Acting Injectable Atypical Antipsychotic Use in Adolescents: An Observational Study. Journal of Child and Adolescent Psychopharmacology 28:4, pages 252-257.
Crossref
Crossref
Seiya Miyamoto & W. Wolfgang Fleischhacker. (2017) The Use of Long-Acting Injectable Antipsychotics in Schizophrenia. Current Treatment Options in Psychiatry 4:2, pages 117-126.
Crossref
Crossref
Leslie Citrome. (2017) Activating and Sedating Adverse Effects of Second-Generation Antipsychotics in the Treatment of Schizophrenia and Major Depressive Disorder. Journal of Clinical Psychopharmacology 37:2, pages 138-147.
Crossref
Crossref
Leslie Citrome. 2017. The Diagnosis and Management of Agitation. The Diagnosis and Management of Agitation
200
218
.
Sarah LytleMolly McVoyMartha Sajatovic. (2017) Long-Acting Injectable Antipsychotics in Children and Adolescents. Journal of Child and Adolescent Psychopharmacology 27:1, pages 2-9.
Crossref
Crossref
Edward Kim, Christoph U. Correll, Lian Mao, H. Lynn Starr & Larry Alphs. (2016) Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia. CNS Spectrums 21:6, pages 466-477.
Crossref
Crossref
A. Bogomolova, L. Kaberov, O. Sedlacek, S.K. Filippov, P. Stepanek, V. Král, X.Y. Wang, S.L. Liu, X.D. Ye & M. Hruby. (2016) Double stimuli-responsive polymer systems: How to use crosstalk between pH- and thermosensitivity for drug depots. European Polymer Journal 84, pages 54-64.
Crossref
Crossref
Chelsea N. Carr, Colleen P. Hall, Jennifer E. Roche-Desilets, Christopher J. Burant & Matthew A. Fuller. (2016) Evaluation of adherence in patients prescribed long-acting injectable antipsychotics: A comparison of biweekly versus monthly administered neuroleptics. Mental Health Clinician 6:5, pages 248-253.
Crossref
Crossref
Nicholas A Keks, Judy Hope & Christine Culhane. (2016) Aripiprazole long-acting injection: promising but more evidence needed. Australasian Psychiatry 24:4, pages 368-370.
Crossref
Crossref
Sourabh Moti Singh, Peter M. Haddad, Nusrat Husain, Eamonn Heaney, Barbara Tomenson & Imran B. Chaudhry. (2016)
Cross-sectional comparison of first-generation antipsychotic long-acting injections
vs
risperidone long-acting injection: patient-rated attitudes, satisfaction and tolerability
. Therapeutic Advances in Psychopharmacology 6:3, pages 162-171.
Crossref
Crossref
Hala El-Haroun. (2016) Microscopic study of a possible ameliorating role of curcumin against the effects of first-generation and second-generation antipsychotic drugs in adult rat cerebral cortex. The Egyptian Journal of Histology 39:1, pages 96-108.
Crossref
Crossref
Yuko Yasuhara, Tetsuya Tanioka, Kensaku Takase, Kazushi Motoki, Chie Watari, Koichi Makiguchi, Asumi Atsuta & Rozzano C. Locsin. (2016) Intramuscular Diffusion Status of Risperidone and Aripiprazole Long Acting Injectable (LAI) by Ultrasonography. Open Journal of Psychiatry 06:02, pages 165-172.
Crossref
Crossref
William M. Greenberg & Leslie Citrome. (2015) Paliperidone Palmitate for Schizoaffective Disorder: A Review of the Clinical Evidence. Neurology and Therapy 4:2, pages 81-91.
Crossref
Crossref
René S. Kahn, Iris E. Sommer, Robin M. Murray, Andreas Meyer-Lindenberg, Daniel R. Weinberger, Tyrone D. Cannon, Michael O'Donovan, Christoph U. Correll, John M. Kane, Jim van Os & Thomas R. Insel. (2015) Schizophrenia. Nature Reviews Disease Primers 1:1.
Crossref
Crossref
L. Citrome. (2015) Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be hel. International Journal of Clinical Practice 69:9, pages 978-997.
Crossref
Crossref
Leslie Citrome & Jan Volavka. (2015) Preventing Violence in Patients with Schizophrenia. Current Treatment Options in Psychiatry 2:2, pages 182-191.
Crossref
Crossref
M.-A. Crocq. (2015) Histoire des traitements antipsychotiques à action prolongée dans la schizophrénie. L'Encéphale 41:1, pages 84-92.
Crossref
Crossref
. (2014) Depot-Antipsychotika in der Rezidivprophylaxe. psychopraxis. neuropraxis 17:6, pages 24-25.
Crossref
Crossref
Leslie Citrome & Jan Volavka. (2014) The psychopharmacology of violence: making sensible decisions. CNS Spectrums 19:5, pages 411-418.
Crossref
Crossref
Daniel C. Javitt. (2014) Current and Emergent Treatments for Symptoms and Neurocognitive Impairment in Schizophrenia. Current Treatment Options in Psychiatry 1:2, pages 107-120.
Crossref
Crossref
L. Citrome. (2014) Formulations: friendly, fast, forgiving and flexible. International Journal of Clinical Practice 68:4, pages 407-407.
Crossref
Crossref
Stephen M. Stahl. (2014) Long-acting injectable antipsychotics: shall the last be first?. CNS Spectrums 19:1, pages 3-5.
Crossref
Crossref
Cynthia A. Mascareñas & Rosana Oliveira. (2013) Dynamics of drug evaluation: Formulary placement of antipsychotics. Mental Health Clinician 3:4, pages 185-187.
Crossref
Crossref